论文部分内容阅读
本文作者于1994年经临床观察证实,阿司匹林(ASA)具有很好的抗血小板作用。过去,根据镇痛解热的药理学,在临床使用ASA剂量较大,为900 mg/d～1500 mg/d,现在,经研究证实小剂量ASA,可抑制血小板环氧化酶,减少TXA_2的形成。由于药物顺应性和个体差异,测定TXB_2含量可反映TXA_2形成的多少,从而证实口服小剂量ASA抗血小板的效果。据文献报告,TXA_2生物合成增加(TXB_2升高)表示冠心病、
The authors in 1994 confirmed by clinical observation, aspirin (ASA) has a good anti-platelet effect. In the past, according to the pharmacology of analgesic and antipyretic, in the clinical use of a large dose of ASA, 900 mg / d ~ 1500 mg / d, now confirmed by the study showed that low-dose ASA can inhibit platelet cyclooxygenase, TXA_2 form. Due to drug compliance and individual differences, the determination of TXB_2 content can reflect the formation of TXA_2 to confirm the low-dose oral anti-platelet effect. According to literature reports, TXA_2 biosynthesis increased (TXB_2 elevated) that coronary heart disease,